GlassScriptPhysician profile
Michael R Allen
NPI 1770947889
$8,480.48
in general payments reported to CMS, 2019-2025
17 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $903 · 2023: $1,434 · 2024: $5,144 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,455 · Food and Beverage: $2,377 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,455.00 |
| Food and Beverage | $2,376.56 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $4,476.24 | 2024 | Arcalyst |
| Abbvie INC. | $1,251.33 | 2021-2024 | Rinvoq, Skyrizi |
| Mallinckrodt Hospital Products INC. | $570.57 | 2021-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $325.07 | 2023-2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $257.12 | 2021-2023 | Benlysta |
| Janssen Biotech, INC. | $249.10 | 2023-2024 | Simponi Aria, Tremfya |
| United Therapeutics Corporation | $245.76 | 2023 | Tyvaso |
| Horizon Therapeutics Plc | $230.35 | 2021-2023 | |
| Ucb, INC. | $223.58 | 2022-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $175.00 | 2022-2023 | Taltz |
| Amgen INC. | $139.86 | 2024-2025 | Tavneos, Uplizna |
| Aurinia Pharma U.S., INC. | $122.88 | 2025 | Lupkynis |
| Pfizer INC. | $80.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.04 | 2021-2023 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.98 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.22 | 2023 | |
| Sobi, INC | $19.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.